FDA lagging on nanotechnology

Share this article:
Former FDA deputy commissioner for policy Michael Taylor says the agency lacks the legal authority and financial and staff resources it needs to properly regulate food, drugs, medical devices, dietary supplements, and cosmetics containing nanotechnology materials.

“The pressures of expanding regulatory responsibilities and the increasing cost of doing business, coupled with the failure of Congress and successive administrations to adequately fund even FDA's base operations, are a real threat to FDA's ability to effectively oversee nanotechnology,” Taylor wrote in a Robert Wood Johnson Foundation report.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions